Insider · CIK 0001825776
Hans T. Schambye
Files at DMRA (Damora Therapeutics, Inc.). First filing Jan 7, 2025, latest Jan 6, 2026.
Hans T. Schambye files SEC Form 4 as CEO and director at DMRA (Damora Therapeutics, Inc.). Since Jan 7, 2025, Hans T. Schambye has reported 0 open-market buys worth $0 and 3 open-market sells worth $25k, the latest filed on Jan 6, 2026.
A track record needs three past buys with six months of prices behind them; Hans T. Schambye has 0, so none is measured yet.
The newest scored trade: sold $15k of DMRA on Jan 2, 2026, filed Jan 6, 2026, scored 30 (weak). In the last 12 months: 0 buys worth $0 and 1 sell worth $15k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
DMRA: Damora Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | Damora Therapeutics, Inc. | $15k 700 shares | -13% | +883% from low-36% from high | |
| 30Weak | Damora Therapeutics, Inc. | $2,484 735 shares | -15% | +59% from low-75% from high | |
| 35Weak | Damora Therapeutics, Inc. | $7,510 1,341 shares | -28% | - |
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 2, 2026 | DMRA Damora Therapeutics, Inc. | MOption exercise Common Stock | +1,360 | - | - | 5,382 | Jan 6, 2026 |
| Jan 2, 2026 | DMRA Damora Therapeutics, Inc. | SOpen-market sale Common Stock | -700 | $21.38 | $15k | 4,682 | Jan 6, 2026 |
| Jan 2, 2026 | DMRA Damora Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -1,360 | $0.00 | $0 | 2,640 | Jan 6, 2026 |
| Jul 3, 2025 | DMRA Damora Therapeutics, Inc. | MOption exercise Common Stock | +1,360 | - | - | 4,757 | Jul 8, 2025 |
| Jul 3, 2025 | DMRA Damora Therapeutics, Inc. | SOpen-market sale Common Stock | -735 | $3.38 | $2,484 | 4,022 | Jul 8, 2025 |
| Jul 3, 2025 | DMRA Damora Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -1,360 | $0.00 | $0 | 4,000 | Jul 8, 2025 |
| Jan 3, 2025 | DMRA Damora Therapeutics, Inc. | MOption exercise Common Stock | +2,640 | - | - | 4,738 | Jan 7, 2025 |
| Jan 3, 2025 | DMRA Damora Therapeutics, Inc. | SOpen-market sale Common Stock | -1,341 | $5.60 | $7,510 | 3,397 | Jan 7, 2025 |
| Jan 3, 2025 | DMRA Damora Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -2,640 | $0.00 | $0 | 5,360 | Jan 7, 2025 |
| Jan 3, 2025 | DMRA Damora Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +16,400 | $0.00 | $0 | 16,400 | Jan 7, 2025 |
| Oct 9, 2024 | DMRA Damora Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +44,100 | $0.00 | $0 | 44,100 | Oct 11, 2024 |
Questions about Hans T. Schambye
Answered from the filings on this page, as of the latest one.
Is Hans T. Schambye buying or selling?
In the last 12 months Hans T. Schambye reported 0 open-market buys worth $0 and 1 open-market sell worth $15k on SEC Form 4; the latest was sold $15k of DMRA on Jan 2, 2026. Grants, option exercises and tax withholding are not counted.
How did Hans T. Schambye's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Hans T. Schambye has 0.
Where does Hans T. Schambye file Form 4?
Hans T. Schambye has filed Form 4 at DMRA (Damora Therapeutics, Inc.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.